Jan H.M. Schellens

59.2k total citations · 14 hit papers
882 papers, 41.1k citations indexed

About

Jan H.M. Schellens is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jan H.M. Schellens has authored 882 papers receiving a total of 41.1k indexed citations (citations by other indexed papers that have themselves been cited), including 564 papers in Oncology, 346 papers in Molecular Biology and 159 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jan H.M. Schellens's work include Cancer Treatment and Pharmacology (184 papers), Colorectal Cancer Treatments and Studies (163 papers) and Cancer therapeutics and mechanisms (139 papers). Jan H.M. Schellens is often cited by papers focused on Cancer Treatment and Pharmacology (184 papers), Colorectal Cancer Treatments and Studies (163 papers) and Cancer therapeutics and mechanisms (139 papers). Jan H.M. Schellens collaborates with scholars based in Netherlands, United States and United Kingdom. Jan H.M. Schellens's co-authors include Jos H. Beijnen, Alwin D. R. Huitema, Hilde Rosing, Dick Pluim, Alfred H. Schinkel, Irma Meijerman, Olaf van Tellingen, David S. Boss, Rolf W. Sparidans and Marja Mergui‐Roelvink and has published in prestigious journals such as New England Journal of Medicine, Cell and Journal of Biological Chemistry.

In The Last Decade

Jan H.M. Schellens

876 papers receiving 40.3k citations

Hit Papers

Inhibition of Poly(ADP-Ri... 2001 2026 2009 2017 2009 2001 2004 2010 2006 500 1000 1.5k 2.0k 2.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
    2009 2.7k citations Peter C.C. Fong, David S. Boss et al. profile →
  2. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.
    2001 920 citations Alfred H. Schinkel, Jan H.M. Schellens et al. profile →
  3. A Phase I and Pharmacological Study with Imidazolium- trans- DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent
    2004 760 citations Dick Pluim, Jos H. Beijnen et al. Clinical Cancer Research profile →
  4. Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval
    2010 745 citations Peter C.C. Fong, Timothy A. Yap et al. Journal of Clinical Oncology profile →
  5. Photodynamic Therapy in Oncology
    2006 619 citations Jan H.M. Schellens et al. profile →
  6. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer
    2017 607 citations Jan H.M. Schellens, Jean Charles Soria et al. Journal of Clinical Oncology profile →
  7. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.
    2002 590 citations Jan H.M. Schellens, Alfred H. Schinkel et al. profile →
  8. Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
    2010 558 citations Alwin D. R. Huitema, Jan H.M. Schellens et al. profile →
  9. Approaching tumour therapy beyond platinum drugs
    2011 450 citations Jan H.M. Schellens, Jos H. Beijnen et al. profile →
  10. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update
    2017 406 citations Jan H.M. Schellens et al. profile →
  11. Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors
    2019 404 citations Neeltje Steeghs, Jos H. Beijnen et al. profile →
  12. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial
    2020 314 citations Ulrik Lassen, Jan H.M. Schellens et al. profile →
  13. Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study
    2018 302 citations Dejan Juric, Jordi Rodón et al. Journal of Clinical Oncology profile →
  14. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study
    2022 183 citations Jan H.M. Schellens, Jean‐Charles Soria et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Jan H.M. Schellens 22.6k 16.1k 6.4k 3.7k 3.6k 882 41.1k
Jos H. Beijnen 27.4k 1.2× 17.7k 1.1× 6.0k 0.9× 3.3k 0.9× 6.0k 1.7× 1.5k 57.9k
Susan E. Bates 22.9k 1.0× 20.1k 1.2× 2.8k 0.4× 4.4k 1.2× 1.5k 0.4× 453 38.5k
Michael M. Gottesman 32.9k 1.5× 27.8k 1.7× 2.2k 0.4× 4.3k 1.1× 3.1k 0.9× 408 53.6k
Zhe‐Sheng Chen 12.7k 0.6× 15.5k 1.0× 2.6k 0.4× 4.0k 1.1× 1.1k 0.3× 591 31.1k
Mark J. Ratain 10.2k 0.5× 9.1k 0.6× 4.3k 0.7× 3.1k 0.8× 2.8k 0.8× 532 23.0k
William D. Figg 10.0k 0.4× 11.5k 0.7× 4.4k 0.7× 3.4k 0.9× 1.3k 0.4× 604 25.3k
Howard L. McLeod 10.1k 0.4× 9.6k 0.6× 2.6k 0.4× 2.9k 0.8× 6.6k 1.9× 481 26.6k
Godefridus J. Peters 16.5k 0.7× 18.0k 1.1× 5.4k 0.9× 5.6k 1.5× 586 0.2× 854 35.0k
Elisabeth G.E. de Vries 24.1k 1.1× 14.3k 0.9× 7.4k 1.2× 6.4k 1.7× 663 0.2× 1.0k 47.8k
Herbert M. Pinedo 15.8k 0.7× 12.1k 0.8× 3.9k 0.6× 3.5k 0.9× 737 0.2× 571 29.8k

Countries citing papers authored by Jan H.M. Schellens

Since Specialization
Citations

This map shows the geographic impact of Jan H.M. Schellens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan H.M. Schellens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan H.M. Schellens more than expected).

Fields of papers citing papers by Jan H.M. Schellens

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan H.M. Schellens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan H.M. Schellens. The network helps show where Jan H.M. Schellens may publish in the future.

Co-authorship network of co-authors of Jan H.M. Schellens

This figure shows the co-authorship network connecting the top 25 collaborators of Jan H.M. Schellens. A scholar is included among the top collaborators of Jan H.M. Schellens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan H.M. Schellens. Jan H.M. Schellens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Heuvel, Michel M. van den, Judi van Diessen, Heike Peulen, et al.. (2020). Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer. Clinical Cancer Research. 27(5). 1256–1266. 39 indexed citations
2.
Hoff, Daniel D. Von, Drew Rasco, Elisabeth I. Heath, et al.. (2018). Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors. Clinical Cancer Research. 24(17). 4072–4080. 27 indexed citations
3.
Juric, Dejan, Jordi Rodón, Josep Tabernero, et al.. (2018). Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. Journal of Clinical Oncology. 36(13). 1291–1299. 302 indexed citations breakdown →
4.
Rosing, Hilde, Rubin Lubomirov, Pablo Avilés, et al.. (2018). Development and validation of a liquid chromatography-tandem mass spectrometry assay for the quantification of lurbinectedin in human plasma and urine. Journal of Pharmaceutical and Biomedical Analysis. 158. 160–165. 5 indexed citations
5.
Janssen, Julie M., Hilde Rosing, Jan H.M. Schellens, et al.. (2018). Therapeutic drug monitoring of small molecule kinase inhibitors in oncology in a real‐world cohort study: does age matter?. British Journal of Clinical Pharmacology. 84(12). 2770–2778. 13 indexed citations
6.
Nuland, Merel van, Andries M. Bergman, Hilde Rosing, et al.. (2018). Impact of age on exposure to oral antiandrogen therapies in clinical practice. Prostate Cancer and Prostatic Diseases. 22(1). 168–175. 6 indexed citations
7.
Kaaij, Rosa T. van der, H.J. Braam, Henk Boot, et al.. (2017). Treatment of Peritoneal Dissemination in Stomach Cancer Patients With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Rationale and Design of the PERISCOPE Study. JMIR Research Protocols. 6(7). e136–e136. 13 indexed citations
8.
Gorelova, Vera, Jeroen Van Daele, Dick Pluim, et al.. (2017). Dihydrofolate Reductase/Thymidylate Synthase Fine-Tunes the Folate Status and Controls Redox Homeostasis in Plants. The Plant Cell. 29(11). 2831–2853. 68 indexed citations
9.
Rood, Johannes J.M., Mark T. J. van Bussel, Jan H.M. Schellens, Jos H. Beijnen, & Rolf W. Sparidans. (2016). Liquid chromatography–tandem mass spectrometric assay for the T790M mutant EGFR inhibitor osimertinib (AZD9291) in human plasma. Journal of Chromatography B. 1031. 80–85. 39 indexed citations
10.
Rood, Johannes J.M., Jan H.M. Schellens, Jos H. Beijnen, & Rolf W. Sparidans. (2016). Recent developments in the chromatographic bioanalysis of approved kinase inhibitor drugs in oncology. Journal of Pharmaceutical and Biomedical Analysis. 130. 244–263. 31 indexed citations
11.
Münster, Pamela N., Rahul Aggarwal, David S. Hong, et al.. (2015). First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies. Clinical Cancer Research. 22(8). 1932–1939. 83 indexed citations
12.
Rood, Johannes J.M., Stéphanie van Hoppe, Alfred H. Schinkel, et al.. (2015). Liquid chromatography–tandem mass spectrometric assay for the simultaneous determination of the irreversible BTK inhibitor ibrutinib and its dihydrodiol-metabolite in plasma and its application in mouse pharmacokinetic studies. Journal of Pharmaceutical and Biomedical Analysis. 118. 123–131. 41 indexed citations
13.
Zimmer, Lisa, Fabrice Barlési, Maria Martinez‐García, et al.. (2014). Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS–RAF Mutations. Clinical Cancer Research. 20(16). 4251–4261. 59 indexed citations
14.
Lassen, Ulrik, Didier Meulendijks, L.L. Siu, et al.. (2014). A Phase I Monotherapy Study of RG7212, a First-in-Class Monoclonal Antibody Targeting TWEAK Signaling in Patients with Advanced Cancers. Clinical Cancer Research. 21(2). 258–266. 32 indexed citations
15.
Moreno, Víctor, David Olmos, Carlos Gomez‐Roca, et al.. (2014). Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study. Clinical Cancer Research. 20(22). 5663–5671. 14 indexed citations
16.
Leijen, Suzanne, Mark R. Middleton, Patricia Tresca, et al.. (2012). Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors. Clinical Cancer Research. 18(17). 4794–4805. 55 indexed citations
17.
Jänne, Pasi A., David S. Boss, D. Ross Camidge, et al.. (2011). Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors. Clinical Cancer Research. 17(5). 1131–1139. 149 indexed citations
18.
Deenen, Maarten J., Jolien Tol, Artur M Burylo, et al.. (2011). Relationship between Single Nucleotide Polymorphisms and Haplotypes in DPYD and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer. Clinical Cancer Research. 17(10). 3455–3468. 150 indexed citations
19.
Fong, Peter C.C., Timothy A. Yap, David S. Boss, et al.. (2010). Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval. Journal of Clinical Oncology. 28(15). 2512–2519. 745 indexed citations breakdown →
20.
Boss, David S., Dick Pluim, Hilde Rosing, et al.. (2009). Phase I Pharmacokinetic and Pharmacodynamic Study of Carboplatin and Topotecan Administered Intravenously Every 28 Days to Patients with Malignant Solid Tumors. Clinical Cancer Research. 15(13). 4475–4483. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jos H. Beijnen Breakdown of academic impact, for papers by Susan E. Bates Breakdown of academic impact, for papers by Michael M. Gottesman Breakdown of academic impact, for papers by Zhe‐Sheng Chen Breakdown of academic impact, for papers by Mark J. Ratain Breakdown of academic impact, for papers by William D. Figg Breakdown of academic impact, for papers by Howard L. McLeod Breakdown of academic impact, for papers by Godefridus J. Peters Breakdown of academic impact, for papers by Elisabeth G.E. de Vries Breakdown of academic impact, for papers by Herbert M. Pinedo
Rankless by CCL
2026